UNSPSC 51385401: Cinchophen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39Y533Z02M, chemically known as 4-quinolinecarboxylic acid, 2-phenyl- (9ci) but generally known as cinchophen, which bears US NIH Compound Identifier 8593. European Medicines Agency schedules Cinchophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06288MIG. The term CINCHOPHEN is an International Non-Proprietary Name.

UNSPSC 51385401 Cinchophen is a Commodity code that appears in state and local procurement activity focused on pharmaceutical products and related health services, though recent opportunities show no direct sourcing of cinchophen itself. Instead, issuing bodies under this code are procuring naloxone, generic pharmaceuticals, over-the-counter products, and pharmacy benefit management services that reflect broader community health and medicaid-related purchasing. The scope includes naloxone procurement for opioid response programs, generic drug supply through established wholesaler networks, and strategic pharmacy initiatives designed to manage prescription fulfillment and costs within state health systems.

State agencies and county health authorities drive activity under the code. Seminole County, Florida solicited naloxone and drug deactivation systems through a competitive IFB in mid-2026, while the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer pharmacy arrangements, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products effective across multiple states including Oregon. Geographic concentration appears strongest in Florida and Minnesota, with Texas involvement in exploratory procurement. The MMCAP opportunity (posted January 20, 2026, due March 26, 2026) is representative of scale: it establishes multi-award frameworks for generic drugs distributed through three authorized wholesalers, requires cGMP and DSCSA compliance, imposes a 3 percent administrative fee, and carries performance penalties of $200 to $1,500 per violation. The Seminole County IFB (posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the county health building and E-Verify compliance.